Navigation Links
Amgen Statement On Government Budget Analysis For Oral-Only Treatments For Dialysis Patients
Date:2/22/2013

THOUSAND OAKS, Calif., Feb. 22, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) notes that an analysis by the Congressional Budget Office released this week shows that, contrary to the implications of past media reports, keeping oral-only drugs in Medicare Part D would actually achieve significant savings over time for both taxpayers and the Medicare program.

As noted by the Government Accountability Office (GAO), it is important that the Centers for Medicare and Medicaid Services (CMS) take the time needed to develop quality metrics and further develop their data systems, both of which are essential to providing quality care for an elderly and chronically ill patient population.

Amgen will continue to advocate for sound federal policies that enhance access to care for these patients.

For more background, please visit Our Perspectives on www.amgen.com.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss , 805-313-6151 (media)
Arvind Sood , 805-447-1060 (investors)

(Logo:  http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Selexis Announces Expansion of R&D License Agreement with Amgen
2. Amgen Outlines Long-Term Strategy
3. Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
4. Amgen To Webcast 2013 Business Review Meeting On February 7
5. Statement from Ralph G. Neas, President and CEO, Generic Pharmaceutical Association, on the Front Page New York Times Story Regarding the Pre-emptive Strikes of Amgen/Genentech to Restrict Access to Affordable and Safe Biosimilars
6. Amgen Backs States Efforts To Enact Biosimilar Legislation That Allows For Substitution And Supports Patient Safety
7. Amgens Full Year 2012 Revenues Increased 11 Percent To $17.3 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $6.51
8. Amgen Announces 31 Percent Increase In 2013 First Quarter Dividend And Increase In Its Share Repurchase Authorization
9. Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
10. Amarantus BioSciences Appoints Amgen Co-Founder Dr. Joseph Rubinfeld to Advisory Board
11. Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2019)... ... ... It’s not hard to see the advantages of being an optimist. Research ... happier, and even healthier. Optimism can also be infectious. Walk into a room filled ... more to optimism, however, than the positive mindset and hopeful outlook. A recent study ...
(Date:7/19/2019)... Texas (PRWEB) , ... July ... ... BayMark Health Services company, announced this week the acquisition of KSPS Medical ... Middletown, KY near Louisville and Bowling Green, KY. The facility, established in ...
(Date:7/19/2019)... ... July 19, 2019 , ... Cloudticity, a pioneer in providing ... Senior Vice President of Business Development. , Whaley will work with healthcare ... technology. , As a technology leader with more than 20 years of experience, ...
Breaking Medicine Technology:
(Date:7/17/2019)... ... ... A medical home care program found that having a single accessible point person ... While this may not sound surprising, a recent two year medical home pilot study ... uncovered several surprising outcomes based on a simple formatted healthcare delivery system. , ...
(Date:7/17/2019)... ... ... Dr. Jonathan Zaidan, MD, FACOG, President of Women’s Excellence discusses a new weight ... airs on Wednesday, July 17ths at 7pm. The show podcast will be available ... discuss the challenges that women face when it comes to weight loss and any ...
(Date:7/13/2019)... ... July 13, 2019 , ... ZALO , the leading ... innovative rechargeable vibrator and clitoral massager. To view the product and its accompanying video ... and most advanced, personal massagers to people around the world,” said Mara Epstein, director ...
(Date:7/13/2019)... (PRWEB) , ... July 12, 2019 , ... ... announced the launch of its proprietary patient management platform, Ospitek “View”. Ospitek has ... center executives to deliver a fully customizable, intelligent, solution made specifically for surgical ...
(Date:7/13/2019)... ... July 12, 2019 , ... China Focus ... Center , sponsored by Hangzhou Investment Promotion Bureau, Fox Rothschild LLP, MORE Health ... The conference attracted Fosun Pharmaceuticals, WuXi Biologics, Kelun Pharmaceutical, Harbin Pharmaceuticals, Fountain Medical, ...
Breaking Medicine News(10 mins):